Alterations in pro-survival BCL2 proteins might have importance beyond cancer genesis as high levels of MCL-1 expression at diagnosis correlate with poor prognosis in breast cancer [96], and MCL-1 amplification is prominent in treatment-resistant breast cancers [97], suggesting that this may be a source of innate and acquired resistance to cancer therapy. The gene discussed is MCL1; the disease is breast carcinoma.